HAVN Life Sciences Inc.
HAVLF
$0.001
$0.000.00%
OTC PK
| 01/31/2023 | 10/31/2022 | 07/31/2022 | 04/30/2022 | 01/31/2022 | |
|---|---|---|---|---|---|
| Revenue | 451.20K | 478.30K | 263.80K | 218.60K | 47.80K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 451.20K | 478.30K | 263.80K | 218.60K | 47.80K |
| Cost of Revenue | 290.50K | 251.20K | 179.10K | 147.70K | 30.60K |
| Gross Profit | 160.70K | 227.10K | 84.70K | 70.90K | 17.20K |
| SG&A Expenses | 2.40M | 3.24M | 4.84M | 5.45M | 8.96M |
| Depreciation & Amortization | 147.80K | 251.90K | 369.20K | 458.50K | 2.49M |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.22M | 4.19M | 5.82M | 6.58M | 11.99M |
| Operating Income | -2.77M | -3.71M | -5.55M | -6.36M | -11.94M |
| Income Before Tax | -12.26M | -13.48M | -16.32M | -17.83M | -17.59M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -12.26 | -13.48 | -16.32 | -17.83 | -17.59 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -12.26M | -13.48M | -16.32M | -17.83M | -17.59M |
| EBIT | -2.77M | -3.71M | -5.55M | -6.36M | -11.94M |
| EBITDA | -2.64M | -3.48M | -5.20M | -5.92M | -9.47M |
| EPS Basic | -2.41 | -2.76 | -3.58 | -4.03 | -4.96 |
| Normalized Basic EPS | -0.45 | -0.65 | -0.97 | -1.25 | -2.76 |
| EPS Diluted | -2.41 | -2.76 | -3.65 | -4.09 | -5.02 |
| Normalized Diluted EPS | -0.45 | -0.65 | -0.97 | -1.25 | -2.76 |
| Average Basic Shares Outstanding | 26.04M | 20.57M | 18.66M | 17.12M | 15.46M |
| Average Diluted Shares Outstanding | 26.04M | 20.57M | 18.66M | 17.12M | 15.46M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |